glp-1 suicidal ideation Depressed mood and thoughts reporting with receptor agonists in type 2 diabetes: A WHO VigiBase study Study: GLP-1 Drugs Don't Raise

Medicaid coverage varies by state, as some state drug utilization data reflects coverage for GLP-1s for weight loss, but it is not universal

The apparent clearance (CL/F) of galcanezumab-gnlm was 0.008 L/h and the elimination half-life of galcanezumab was approximately 27 days

PRISMA chart is depicted in Fig

The Ministry of Health and Long-Term Care perspective was taken, and all costs are expressed in 2013 Canadian dollars

Moreover, we also searched preprint platform to avoid publication bias

The Potential ROI for Covering GLP-1s, Workspan Daily Plus+ article Beyond the Rx: Maximizing GLP-1 Value Through Employee Support, Workspan Daily Plus+ article A Prescription for Rising Drug Costs, Workspan Magazine article For Everyone What Does the Data Show on GLP-1 Prescribe Rates, Coverage, Costs